1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Horizon's Revised TED Indication Should Help Tepezza

Good News For Amgen, But Viridian Looms As Competition

 
• By Joseph Haas

With Tepezza now clearly labeled for all thyroid eye disease patients, rather than just acute cases, Amgen can be more optimistic about economics around of its Horizon acquisition, analysts suggest.

eye disease
Revised indication for Tepezza should mean broader patient access within TED • Source: Shutterstock

Just four days after unveiling top-line data from a Phase IV study on the efficacy of thyroid eye disease (TED) drug Tepezza, Horizon Therapeutics plc got an updated indication from the US Food and Drug Administration for the biologic, which analysts said might encourage payers to cover the drug in patients with less-severe disease. Tepezza (teprotumumab) is a key driver of Amgen, Inc.’s $27.8bn buyout of Horizon, and analysts said broader use is necessary to assure the deal is viable financially.

The updated indication specifies that Tepezza is appropriate for treatment of both acute and chronic TED, a progressive, vision-threatening rare autoimmune disease. The initial indication covered TED broadly; Horizon ran...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Kymera STAT6 Data Set The Bar For ‘Dupixent-In-A-Pill’ Race

 
• By Jessica Merrill

Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.

ASCO: Zepzelca Tecentriq Combo A Lung Cancer Success For Jazz and Roche

 
• By Andrew McConaghie

Small-cell lung cancer treatment is rapidly evolving, but Jazz and Roche are set to create a new maintenance therapy setting with their Zepzelca plus Tecentriq combination.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

More from R&D

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.